Insulin Resistance Panel

Your fasting blood sugar can look perfectly normal for a decade while your body quietly loses its ability to process sugar efficiently. The problem starts not with sugar itself but with insulin, the hormone your pancreas releases to move sugar from your blood into your cells. When cells stop responding to insulin properly, a condition called insulin resistance, your pancreas compensates by pumping out more and more insulin. Blood sugar stays in range, but the metabolic machinery underneath is already breaking down.

This panel catches that hidden breakdown. By measuring insulin alongside glucose and pairing them with calculated resistance scores, liver enzymes, and blood fats, it reveals the full arc of metabolic dysfunction, from early resistance all the way to organ-level damage. A standard glucose or HbA1c test alone would miss most of this story.

What This Panel Reveals

The panel covers three overlapping domains: how resistant your cells have become to insulin, whether that resistance is already affecting your blood sugar control, and whether your liver and fat metabolism are showing signs of strain.

The resistance scores (HOMA-IR and TyG Index) are the centerpiece. HOMA-IR uses your fasting insulin and glucose together in a formula that estimates how hard your pancreas is working to keep blood sugar stable. A higher score means your pancreas is producing more insulin than it should need to, a sign that your cells are not responding well. The TyG Index pairs your fasting triglycerides (a type of blood fat) with glucose, offering a second, independent estimate of resistance. In a large meta-analysis, higher TyG Index values were associated with approximately a 2.5-fold increased risk of developing type 2 diabetes.

Blood sugar markers round out the picture. Fasting glucose tells you what your blood sugar is doing right now. HbA1c measures how much glucose has attached to your red blood cells over the past two to three months, giving you a rolling average of blood sugar control. Together, they show whether resistance has already started to erode glucose management.

The liver enzymes (ALT and AST) and triglycerides act as damage sensors. When insulin resistance develops, the liver is one of the first organs affected. Fat accumulates in liver cells, a condition called fatty liver disease (now medically termed MASLD, previously known as NAFLD). Elevated ALT, in particular, tracks closely with liver fat content. In the Framingham Offspring Study, participants with elevated ALT had a significantly higher incidence of new-onset metabolic syndrome and type 2 diabetes during follow-up.

How to Read Your Results Together

No single test on this panel tells the full story. The value is in the patterns. Here are the most common result combinations and what they mean.

A rising HOMA-IR with normal glucose is the single most valuable early warning this panel provides. Data from the Whitehall II cohort, which followed over 6,500 adults, showed that insulin resistance begins to rise as early as 13 years before a type 2 diabetes diagnosis, while fasting glucose remains flat until roughly three years before diagnosis. That is a decade of silent metabolic deterioration that only shows up if you measure insulin directly.

When Results Can Be Misleading

Several things can temporarily shift these results in ways that do not reflect your true metabolic state. A high-carbohydrate meal the evening before a fasting blood draw can raise both glucose and insulin, inflating your HOMA-IR. Alcohol consumption in the 48 hours before testing can elevate ALT and AST independently of liver fat. Acute illness, infection, or significant physical stress can raise glucose, triglycerides, and liver enzymes simultaneously.

Certain medications also interfere. Corticosteroids raise blood sugar and can worsen insulin resistance acutely. Statins can modestly elevate ALT. Thiazide diuretics and some beta-blockers can raise glucose and triglycerides. If your results are unexpectedly abnormal and you take any of these, a repeat test after discussing timing with your prescriber is reasonable.

HbA1c can be falsely low or high in conditions that change how long red blood cells survive. Iron deficiency anemia, for example, can artificially raise HbA1c. Inherited hemoglobin differences, more common in some ethnic groups, can also cause certain testing methods to give inaccurate HbA1c readings.

Tracking Over Time

A single set of results gives you a snapshot. Repeated testing turns this panel into a trend line that reveals the direction and speed of metabolic change. A HOMA-IR that rises from 1.5 to 2.5 over 18 months tells you something very different from a HOMA-IR that has been stable at 2.5 for three years.

Tracking is especially valuable after lifestyle interventions. If you start an exercise program or change your diet, repeating the panel at three to six months shows you whether the intervention is actually improving insulin sensitivity, not just lowering your weight. Research from the Diabetes Prevention Program showed that lifestyle intervention reduced the incidence of diabetes by 58% compared to placebo over roughly three years, and tracking insulin resistance markers helps confirm that you are among the responders.

For people on diabetes or weight-loss medications, the panel also tracks treatment response. A falling HOMA-IR and normalizing triglycerides confirm the medication is reaching its target. Persistent elevation despite treatment signals the need for a dose change or combination therapy.

What to Do with Your Results

Elevated resistance scores with normal glucose and HbA1c place you in the earliest, most reversible stage. Lifestyle changes, including regular exercise and dietary adjustment, are the most effective intervention at this point. If ALT is also elevated, a liver ultrasound can check for fat accumulation, since fatty liver disease affects roughly one in four adults worldwide and often progresses without symptoms. Catching it early, before scarring develops, gives you the widest range of reversible options.

If HbA1c has entered the prediabetes range (5.7% to 6.4%), discuss next steps with your physician. Adding an NMR Lipoprofile can reveal whether insulin resistance is changing cholesterol particle sizes in ways that standard testing misses.